Pricing Policies Mean Cheap Drugs Dominate Turkish Market
This article was originally published in PharmAsia News
The Turkish government’s unrelenting policies to curb prices in the local pharmaceutical industry are having a big impact on the shape of the market. While demand for the cheapest products is strengthening, the market share of drugs with a higher price tag is becoming marginalized. Meanwhile, the industry is still unhappy with changes to the fixed Euro exchange rate.
You may also be interested in...
Turkey’s efforts to control rising rates of COVID-19 are compromising the ability of hospitals to pay their debts to medtech and pharmaceutical companies. The government has devised a payments plan, but there is catch.
The Turkish medtech industry’s ongoing hospital payments problems appeared likely to come back onto the government’s agenda, with the national economy recovering somewhat in late 2019. But COVID-19 dashed those hopes.
Growth prospects for Turkey’s medical technology market are significant, but local companies have complained about public policies that are harmful to business and about the ongoing crisis in the hospital system. Now, international medtechs are starting to react, with some downscaling local operations and portfolios. Association of Research Based Medical Technologies Manufacturers president Umut Gokalp laid out the problems being faced by industry, and what action he thinks the government should take.